Mutated anti-cd22 antibodies and immunoconjugates
First Claim
9. A chimeric molecule comprising (a) an antibody that specifically binds CD22, said anti-CD22 antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs) designated in order from the CDR closest to the amino terminus to the CDR closest to the carboxyl terminus CDRs 1, 2, and 3, wherein said CDR1 has a sequence selected from the group consisting of SEQ ID NOs:
- 7, 8, 9, and 10; and
(b) a therapeutic moiety or a detectable label.
1 Assignment
0 Petitions
Accused Products
Abstract
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.
38 Citations
105 Claims
-
9. A chimeric molecule comprising
(a) an antibody that specifically binds CD22, said anti-CD22 antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs) designated in order from the CDR closest to the amino terminus to the CDR closest to the carboxyl terminus CDRs 1, 2, and 3, wherein said CDR1 has a sequence selected from the group consisting of SEQ ID NOs: - 7, 8, 9, and 10; and
(b) a therapeutic moiety or a detectable label. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
- 7, 8, 9, and 10; and
-
25. A use of an antibody that specifically binds CD22, said anti-CD22 antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs), said CDRs designated in order from the CDR closest to the amino terminus to the CDR closest to the carboxyl terminus as CDRs 1, 2, and 3, respectively, wherein said CDR1 has a sequence selected from the group consisting of SEQ ID NOs:
- 7, 8, 9, and 10, for the manufacture of a medicament to inhibit the growth of a CD22+ cancer cell.
- View Dependent Claims (26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
- 37. An isolated nucleic acid encoding a variable light (VL) chain comprising three complementarity determining regions (CDRs), said CDRs being designated in order from the CDR closest to the amino terminus to the CDR closest to the carboxyl terminus as CDRs 1, 2, and 3, respectively, wherein said CDR1 has a sequence selected from the group consisting of SEQ ID NOs:
-
52-1. An expression vector comprising a nucleic acid of claim 46 operably linked to a promoter.
-
53. A method of inhibiting growth of a CD22+ cancer cell by contacting said cell with a chimeric molecule comprising (a) an antibody that binds to CD22, said antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs), said CDRs designated in order from the CDR closest to the amino terminus to the CDR closest to the carboxyl terminus CDRs 1, 2, and 3, respectively, wherein said CDR1 has a sequence selected from the group consisting of SEQ ID NOs:
- 7, 8, 9, and 10, and (b) a therapeutic moiety,
wherein said therapeutic moiety inhibits the growth of said cell. - View Dependent Claims (54, 55, 56, 57, 58, 59, 60, 61, 62, 63)
- 7, 8, 9, and 10, and (b) a therapeutic moiety,
-
64. A method for detecting the presence of a CD22+ cancer cell in a biological sample, said method comprising:
-
(a) contacting cells of said biological sample with a chimeric molecule comprising (i) an antibody that specifically binds to CD22, said antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs), said CDRs designated in order from the CDR closest to the amino terminus to the CDR closest to the carboxyl terminus CDRs 1, 2, and 3, respectively, wherein said CDR1 has a sequence selected from the group consisting of SEQ ID NOs;
7, 8, 9, and 10, conjugated or fused to(ii) a detectable label; and
,(b) detecting the presence or absence of said label, wherein detecting the presence of said label indicates the presence of a CD22+ cancer cell in said sample. - View Dependent Claims (65, 66, 67, 68)
-
-
69. A kit comprising:
-
(a) a container, and (b) a chimeric molecule comprising (i) an anti-CD22 antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs), said CDRs designated in order from the CDR closest to the amino terminus to the CDR closest to the carboxyl terminus CDRs 1, 2, and 3, respectively, wherein said CDR1 has a sequence selected from the group consisting of SEQ ID NOs;
7, 8, 9, and 10, conjugated or fused to(ii) a detectable label or a therapeutic moiety. - View Dependent Claims (70, 71, 72, 73, 74)
-
- 75. A Pseudomonas exotoxin A or a cytotoxic fragment or mutant thereof, wherein said PE has a glycine, alanine, valine, leucine, or isoleucine in place of arginine at the position corresponding to position 490 of SEQ ID NO:
-
78. A chimeric molecule comprising a targeting moiety conjugated or fused to a Pseudomonas exotoxin A or a cytotoxic fragment or mutant thereof (“
- PE”
), wherein said PE has a glycine, alanine, valine, leucine, or isoleucine in place of arginine at a position corresponding to position 490 of SEQ ID NO;
24. - View Dependent Claims (79, 80, 81, 82, 83, 84)
- PE”
-
85. An isolated nucleic acid encoding Pseudomonas exotoxin A or cytotoxic fragment or mutant thereof (“
- PE”
), wherein said PE has a glycine, alanine, valine, leucine, or isoleucine in place of arginine at a position corresponding to position 490 of SEQ ID NO;
24. - View Dependent Claims (86, 87, 88, 89, 90, 91, 92, 93, 94)
- PE”
-
95. A use of a targeting moiety conjugated or fused to Pseudomonas exotoxin A or a cytotoxic fragment or a mutant thereof (“
- PE”
), wherein said PE has a glycine, alanine, valine, leucine, or isoleucine in place of arginine at a position corresponding to position 490 of SEQ ID NO;
24, for the manufacture of a medicament to inhibit the growth of cells targeted by said targeting moiety. - View Dependent Claims (96, 97, 98, 99)
- PE”
-
100. A method of inhibiting the growth of a cell bearing a target molecule, said method comprising contacting said cell with a chimeric molecule comprising
(a) a targeting moiety that binds to said target molecule, and (b) Pseudomonas exotoxin A or a cytotoxic fragment or mutant thereof (“ - PE”
), wherein said PE has a glycine, alanine, valine, leucine, or isoleucine in place of arginine at a position corresponding to position 490 of SEQ ID NO;
24, wherein contacting said cell with said chimeric molecule inhibits the growth of said cell. - View Dependent Claims (101, 102, 103, 104, 105)
- PE”
Specification